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The  Transforming  Growth  Factor-beta  (TGF)  pathway  mediates  a broad  spectrum  of cellular  processes
and is involved  in several  diseases,  including  cancer.  TGF  has a dual  role  in  tumours,  acting  as  a tumour
suppressor  in  the  early  phase  of  tumorigenesis  and  as  a  tumour  promoter  in  more  advanced  stages.  In
this review,  we discuss  the  effects  of  TGF-driven  transcription  on all stages  of tumour  progression,
with  special  focus  on lung  cancer.  Since  some  TGF target  genes  are  speciﬁcally  involved  in promotingeywords:
GF
ancer
etastasis
ranscription
MT
metastasis,  we  speculate  that  these  genes  might  be good  targets  to block  tumour  progression  without
compromising  the tumour  suppressor  effects  of  the  TGF  pathway.
© 2016  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY license  (http://creativecommons.
org/licenses/by/4.0/).mmunosurveillance
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. Introduction cytokine secretion and motility in cancer cells, thus playing a keyPlease cite this article in press as: G. Cantelli, et al., TGFB-i
http://dx.doi.org/10.1016/j.semcancer.2016.08.009
The TGF signalling pathway mediates cell proliferation, apo-
tosis, differentiation, extracellular matrix (ECM) production,
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TGF2 and TGF3 belong to the TGF superfamily, which also
includes other growth factors such as bone morphogenic proteins
(BMPs), growth and differentiation factors (GDFs), activins and thenduced transcription in cancer, Semin Cancer Biol (2016),
anti-mullerian hormone (AMH) [1].
TGF ligand binding results in the formation of a hetero-
tetrameric complex of type I and type II serine/threonine kinase
receptors, where the constitutively active type II receptor phos-
tp://creativecommons.org/licenses/by/4.0/).
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cig. 1. Canonical TGF signalling. Diagram summarising canonical TGF signalling. T
f  R-SMADs. Active R-SMADs bind to SMAD4 to form a heterotrimer that localises t
horylates and activates the type I receptor. Among the different
ypes of type I and type II receptors, TGF preferentially sig-Please cite this article in press as: G. Cantelli, et al., TGFB-i
http://dx.doi.org/10.1016/j.semcancer.2016.08.009
als through Activin receptor-like kinase 5 (ALK5) type I receptor
nd the TGF type II receptor [4,5]. Once activated, type I TGF
eceptors phosphorylate members of the R-SMAD family, typi-
ally SMAD2 and SMAD3. Phosphorylated R-SMADs associate withigand binding leads to receptor activation, which in turn leads to phospho-activation
nucleus, where it drives transcription with the help of several cofactors.
SMAD4 to form hetero-trimers. Subsequently, they translocate to
the nucleus where, in collaboration with other transcription fac-nduced transcription in cancer, Semin Cancer Biol (2016),
tors, they regulate transcription of several target genes [6,7] (Fig. 1).
TGF-driven transcription is ﬁne-tuned by adaptors, co-activators
and co-factors, which are cell- and context-speciﬁc, explaining
the variety of biological responses elicited by TGF stimulation
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8]. TGF has also been shown to signal independently of SMADs
y directly activating RhoA GTPase [9,10] or alternative signalling
athways [11–13]. In this review, we will ﬁrst discuss the role of
GF in lung cancer, and then we will expand to other epithelial
ancers such as hepatocellular carcinoma (HCC), breast cancer and
rostate cancer, and two aggressive non-epithelial cancers in which
GF plays an important role, glioblastoma and melanoma.
Lung cancer is one of the leading causes of cancer-related
ortality worldwide. There are two main types of lung can-
er, small-cell lung cancer (SCLC) and non-small cell lung cancer
NSCLC), the latter being the most common. Because of the asymp-
omatic course of the disease, most cases are diagnosed at advanced
tages, when surgery is no longer an option. Despite the recent
dvances in lung cancer research, the 5-year survival rate among
SCLC patients remains around 15% [14]. Therefore, a deeper
nderstanding of the molecular mechanisms underlying lung can-
er development and progression is needed to develop more
ffective therapeutic options.
. TGF signalling in early stages of cancer development
.1. The TGF  ˇ paradox
TGF plays contrasting roles in cancer, acting as a tumour sup-
ressor during the ﬁrst stages of tumorigenesis and as a tumour
romoter during advanced stages of progression [15–17]. This
pparent paradox can be explained by the fact that while some
umours develop TGF-inactivating mutations and progress in a
GF-independent manner [18], others accumulate mutations in
umour suppressor genes that operate downstream of TGF sig-
alling. Cancer cells that acquire these mutations gain a great
dvantage over their non-mutated counterparts, as they can exploit
he wide range of pro-tumorigenic effectors downstream of TGF
timulation [16].
For instance, lung cancer cells have been shown to epigenet-
cally silence the TGF co-receptor Endoglin in order to exploit
he pro-invasive and pro-metastatic effects of TGF [19]. More-
ver, p53 suppresses the tumour-suppressive functions of TGF
nd promotes its pro-metastatic role in lung cancer by regulating
peciﬁc sets of TGF regulated genes [20]. Similarly, HCC cells epi-
enetically downregulate TGF target gene HEYL, which is thought
o suppress tumorigenesis by promoting p53-mediated apoptosis
21]. TGF is also a well-established tumour suppressor in the early
tages of breast cancer progression [22–24]. However, TGF shifts
o a pro-metastatic role at later stages: this switch has been shown
o be mediated by the Src regulator PEAK1 [25], highlighting impor-
ance of signalling pathway crosstalk during cancer progression.
.2. TGFˇ signalling in angiogenesis
Many tumours are able to induce new blood vessel formation,
n a process known as angiogenesis (Fig. 3). Angiogenesis allows
xygen and nutrients to reach the inner, less perfused regions of
olid tumours [26]. TGF secreted by stromal cells as well as by
ancer cells themselves has been shown to promote angiogenesis
27,28]. For instance, TGF-driven transcription has been shown
o induce angiogenic factors such as VEGF and CTGF in lung can-
er and in HCC [29–31]. Moreover, in prostate cancer inhibition of
GF-driven transcription by apigenin decreases VEGF production
nd overall impaired progression [32]. VEGF expression is similarly
ontrolled by TGF-driven transcription in glioblastoma [33,34].Please cite this article in press as: G. Cantelli, et al., TGFB-i
http://dx.doi.org/10.1016/j.semcancer.2016.08.009
lioblastoma-secreted TGF also increases expression of insulin-
ike growth factor-binding protein 7 (IGFBP7) in endothelial cells,
romoting angiogenesis [35]. Conversely, endothelial cells stimu-
ate TGF signalling in glioblastoma cells, promoting cell migration PRESS
r Biology xxx (2016) xxx–xxx 3
[36]. Furthermore, in melanoma TGF signalling leads to IL-8 secre-
tion, which also supports angiogenesis and capillary formation
[37].
2.3. TGFˇ signalling and cancer-associated ﬁbroblasts
Cancer cells have a profound impact on their microenviron-
ment by promoting the expression and secretion of components of
the ECM, matrix metalloproteases (MMPs) and cytokines [1,5,38].
Cancer-associated ﬁbroblasts (CAFs) are one of the most important
stromal cells in the tumour microenvironment. Indeed, differ-
ent cell types can become CAFs in response to signals from
cancer cells, such as TGF [39]. CAFs can promote EMT, both
by secreting molecules directed to cancer cells and by remod-
elling the tumour microenvironment through the secretion of
MMPs  and helping local invasion [40,41]. In particular, epithe-
lial cancer cells have been shown to induce the production
of MMP9  by stromal ﬁbroblasts, leading to the remodelling of
the ECM and TGF-driven cancer progression [42,43]. More-
over, TGF from cancer cells induces the expression of MMP1
and ﬁbronectin (FN1) in CAFs [44,45]. TGF also allows for
CAFs to acquire pro-invasive qualities. For instance, TGF allows
CAFs to form functional ﬁlopodia and consequently to invade
the tumour microenvironment, gaining proximity with cancer
cells [46]. Similarly, TGF increases actomyosin contractility in
ﬁbroblasts by promoting LIF expression [47]. LIF subsequently
promotes a pro-invasive phenotype in CAFs by epigenetically
activating JAK/STAT signalling, resulting in ECM remodelling and
formation of tracks that invading cancer cells follow into the
local microenvironment [48,49]. Finally, CAFs reaching proximity
with cancer cells allow them to carry out pro-tumorigenic func-
tions, such as supporting inﬂammation [50], angiogenesis [51]
and tumour initiation [52]. CAFs can also be recruited at sec-
ondary tumour sites, where they support metastasis formation
[53]. For instance, metastatic breast cancer cells induce CAFs to pro-
duce POSTN by secreting TGF, thus promoting lung colonisation
[54].
In summary, as well as being an established driver of cell motil-
ity and local invasion in both epithelial and non-epithelial cells,
TGF signalling supports cancer-associated phenotypes in ﬁbrob-
lasts. In turn, this promotes EMT, enhancing local invasion and thus
promoting tumour progression.
3. TGF signalling and immune response in cancer
Cancer progression is dependent on escaping immunosurveil-
lance. TGF has been shown to maintain immune tolerance and to
support tumour-promoting immune cell functions [55,56], which
are key to tumour progression (Fig. 2). TGF also plays an important
role in the immune system independently of cancer progression by
preventing autoimmune response as well as by regulating T cell
development, differentiation and proliferation [57]. For instance,
TGF mediates the differentiation of T helper (Th) cells into Th2
by repressing the transcriptional activity of T-bet and GATA3 [58].
Moreover, TGF can induce apoptosis in lymphocytes by activating
the lipid phosphatase SHIP [59,60] and can block dendritic cell (DC)
maturation [61].
While the role of TGF secreted by tumour cells on the immune
system has been widely studied, it is also important to consider that
TGF can also be secreted by immune cells. In particular, tumour-
associated macrophages (TAMs) and myeloid-derived suppressornduced transcription in cancer, Semin Cancer Biol (2016),
cells (MDSC) secrete TGF into the tumour microenvironment
[62]. Deletion of the type II TGF receptor in breast cancer cells
leads to MDSCs inﬁltrating into the invasive front of the tumour,
where they promote metastasis by producing TGF [63]. Hence,
ARTICLE IN PRESSG ModelYSCBI-1268; No. of Pages 10
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Fig. 2. TGF signalling effects on immune cells. Diagram showing how TGF signalling affects immune cell compartments in the tumour microenvironment. TGF can
induce monocyte recruitment and then further differentiate and polarize them into M2  tumour-associated macrophages (TAMs). These M2 TAMs can in turn secrete TGF
supporting tumour promotion. TGF can also stimulate neutrophil chemoattraction and then induce a tumour-promoting type of those granulocytes which is called N2
tumour-associated neutrophils (TANs). TGF signalling can inhibit effector functions of dendritic cells (DC) or induce their apoptosis. TGF inhibits the cytotoxic function
of  natural killer cells (NK) by down-regulating the NK-speciﬁc receptor, NKG2D. Moreover, TGF represses cytotoxic gene expression, namely granzyme A, granzyme B,
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terforin, IFN- and FasL in cytotoxic T cells (CTLs). TGF can also act on T helper c
upports  their phenotype and suppressive functions. In addition to tumour-derive
umour  cells evade immune surveillance and sustain tumour progression.
oth tumour-derived or host immune-cell derived TGF can exert
umour-promoting roles acting on various immune cell popula-
ions.
.1. Innate immune cells
TGF affects macrophages and their precursors, monocytes.
GF can also affect neutrophils the master regulators of inﬂam-
ation and DCs, the professional antigen-presenting cells (Fig. 2).
GF stimulates monocyte migration [64] and promotes a de-
ctivated or resting status in macrophages, resulting in a altered
mmune response [65]. Additionally, tumour-derived TGF can
nduce tumour-associated macrophage (TAM) polarization by sup-
ressing nitric oxide [66–69]. Tumour-derived TGF also promotes
umour-associated neutrophils (TANs) [70]. TANs are classiﬁed
s N1 (anti-tumorigenic) and N2 (pro-tumorigenic) neutrophils;
locking TGF reduces N1 TAN inﬁltration, which in turn decreasesPlease cite this article in press as: G. Cantelli, et al., TGFB-i
http://dx.doi.org/10.1016/j.semcancer.2016.08.009
ctivation of intra-tumoral CD8+T cells [70]. Finally, tumour-
erived TGF induces DC apoptosis and inhibits DC migration in
rimary and secondary lymphoid organs as well as in metastatic
umour-draining lymph nodes [71–73].ferentiation. It induces FOXP3 expression in induced T regulatory cells (Treg) and
, myeloid-derived suppressor cells (MDSC) can secrete TGF as well. This helps
3.2. Innate-like lymphocytes
NK cells are cytotoxic innate lymphoid cells (ILC) [74]. NK cyto-
toxicity is mediated by NK-speciﬁc receptors and co-receptors such
as NKp46, NKp30, NKp44 and NKG2D, which serve as activating sur-
face molecules [75]. TGF down-regulates NKp30 and NKG2D in
human NK cells, thus inhibiting NK-mediated DC killing [76]. Simi-
larly, in lung and colorectal cancers TGF plasma levels and NKG2D
levels on NK cells are negatively correlated [77]. Since TGF down-
regulates activating surface molecules in NK cells, it can impair
the recognition of tumour cells by NK cells and thus impede NK-
mediated cytolysis and clearance of tumour cells (Fig. 2).
3.3. Adaptive immune cells
TGF secreted by cancer cells can also impact T cell activity by
regulating their transcriptional proﬁle. TGF directly targets cyto-
toxic T cells (CTLs) through transcriptional repression of cytotoxicnduced transcription in cancer, Semin Cancer Biol (2016),
genes, such as perforin, granzyme A, granzyme B, IFN- and FasL,
resulting in tumour cell escape from immunosurveillance [78]. As
a consequence, blockade of TGF signalling in T cells supports
tumour-speciﬁc CD8+ cytotoxic T cells and promotes tumour eradi-
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ation in vivo [79]. Moreover, knocking out TGF in mice or deleting
MAD family members in T cells result in altered T-cell homeostasis
nd thus promotes cancer initiation [80–83].
One of the most important roles of TGF in promoting tumour
scape from immunosurveillance is sustaining Tregs, which are
ediators of self-tolerance [84] and support immunosuppres-
ion [85]. TGF induces FOXP3 expression and thus maintains
D4+CD25+FOXP3+ Tregs and their immunosuppressive functions
hrough SMAD3 and NFAT mediated transcription [86–88]. More-
ver, TGF secreted by lung cancer cells induces Treg cells in
he lung tumour microenvironment [66]. In HCC, TGF has been
eported to promote the differentiation of Tregs, whereas block-
de of TGF decreases Tregs in liver tissues in vivo, thus reducing
CC progression [89]. In addition to Tregs, TGF also induces Th17
ells, which are involved in inﬂammation [90,91] and it can inhibit
L-2-dependent T cell proliferation [92] (Fig. 2).
. TGF signalling in cancer metastasis
.1. TGFˇ signalling in cancer cell motility and local invasion
Metastasis is the spreading of cancer cells throughout the body
nd is the main cause of cancer-related deaths [93]. It is a multi-step
rocess where cancer cells leave the primary tumour, disseminate
o distant sites and form secondary tumours [94] (Fig. 3). During
he initial stages of metastasis, tumour cells lose cell–cell con-
acts and acquire migratory abilities, invading the local tumour
icroenvironment. During Epithelial to Mesenchymal Transition
EMT), expression of epithelial cell–cell adhesion proteins such as
-cadherin, ZO-1 and occludin is down-regulated, while mesenchy-
al  proteins like N-cadherin are up-regulated. This switch in gene
xpression is regulated by the Snail/Slug, ZEB1/2 and Twist tran-
cription factors [1,5,38]. EMT  not only induces “mesenchymal”
otile characteristics in cancer cells, but also supports tumour ini-
iation, host immunosurveillance evasion and chemoresistance [5]
Fig. 3).
TGF is a key driver of EMT  in epithelial cancers [12,95,96]. In
ung cancer, TGF-driven transcription regulates E-cadherin [97],
nail [98], N-cadherin [99] and vimentin [99–104]. Similarly, TGF
nduces EMT  in breast cancer cells, where it induces the expres-
ion of Sox4, thus promoting mesenchymal programmes, tumour
rogression and invasiveness [105]. TGF signalling also induces
P1 expression, which in turn regulates various mesenchymal and
nvasion-associated genes [106]. Importantly, TGF-induced Snail
r Twist1 can in turn drive epigenetic changes that inﬂuence EMT
105]. Moreover, TGF regulates gene expression of integrins both
n lung and breast cancer, resulting in increased cell motility, dis-
emination and metastasis [98,107–109]. In HCC, EMT  driven by
GF promotes cell dissemination and intrahepatic metastasis, in
ollaboration with other signalling pathways. TGF promotes EMT
y inducing SNAIL1, conferring resistance to apoptosis [110]. Addi-
ionally, autocrine TGF promotes CXCR4 expression in HCC cells,
riving cell migration and invasion [111], while TGF secreted
rom tumour associated macrophages (TAMs) induces cancer stem
ell properties in HCC [112]. Furthermore, in prostate cancer TGF
epresses E-cadherin and promotes the expression of N-cadherin,
EB1, TWIST, ﬁbronectin and SNAIL1 [113–115]. TGF also sup-
orts EMT  in prostate cancer cells by regulating NEDD9 [116].
In addition to epithelial cancers, TGF signalling also drives cell
otility and local invasion in non-epithelial cancers. Glioblastoma,
 grade IV malignant glioma that arises from glial cells, is one of thePlease cite this article in press as: G. Cantelli, et al., TGFB-i
http://dx.doi.org/10.1016/j.semcancer.2016.08.009
ost common and aggressive brain tumours and it is characterised
y its ability to inﬁltrate adjacent healthy brain [117,118]. Glioblas-
omas are highly heterogeneous and can be classiﬁed into different
ub-types, namely mesenchymal, classical, neural and pre-neural. PRESS
r Biology xxx (2016) xxx–xxx 5
In particular, mesenchymal glioblastoma presents with the highest
correlation with EMT-related genes [119]. TGF has been shown to
activate EMT  drivers ZEB1 and SNAIL1 in glioblastoma, thus pro-
moting motility and local invasion [120,121]. Furthermore, TGF
drives the expression of LIF through SMAD-mediated transcription
in glioma-initiating cells [122]. LIF activates JAK/STAT signalling,
promoting glioma cell self-renewal [122]. Moreover, TGF pro-
motes glioblastoma cell motility by transcriptionally activating
surface molecules such as cadherin-11 [36] and integrins [123],
which can feed back to TGF-driven transcription by affecting
SMAD2 activation [124].
Mesenchymal tumours switch between different modes of
individual migration [125]. In particular, melanoma cells switch
between rounded-amoeboid motility, driven by actomyosin con-
tractility, and elongated-mesenchymal motility, dependent on
higher levels of Rac dependent adhesion [126]. TGF-SMAD2-
CITED1-mediated transcription promotes melanoma amoeboid
invasion [127]. Speciﬁcally, TGF-SMAD2-CITED1 regulate expres-
sion of LIF and JAK1 [47,127] and of the RhoGEF ARHGEF5 [128],
both of which support actomyosin contractility [127,129]. TGF
signalling also favours detachment of melanoma cells from ker-
atinocytes [127], which is necessary for melanomas to escape the
epithelial niche and invade into the dermal layers. Perhaps as a con-
sequence of its role in regulating amoeboid motility, TGF-driven
transcription has been widely recognised as a promoter of invasion
in melanoma [130–135]. Since lung cancer has also been described
to engage in amoeboid invasive strategies [136], it will be impor-
tant to assess if TGF controls this particular invasive behaviour in
lung cancer cells.
4.2. TGFˇ signalling in crossing the endothelial barrier
Following local invasion, cancer cells enter blood or lymphatic
vessels in a process known as intravasation [137]. The blood
ﬂow subsequently transports cancer cells throughout the body,
until they exit the vasculature and form secondary tumours [138]
(Fig. 3). In breast cancer, TGF-induced EMT  activates CCR7/CCL21-
mediated chemotaxis, which promotes targeted migration through
lymphatic vessels [139]. While the role of TGF in intravasation
remains unclear, it has been suggested that TGF-driven transcrip-
tion is able to regulate cancer cell extravasation in lung, breast
cancer and HCC cells [140–142]. Moreover, in melanoma TGF-
driven transcription promotes adhesion to endothelial cells [127],
as well as extravasation [130,141]. On the other hand, TGF also
favours cell extravasation by acting directly on the endothelium.
For example, TGF activates transcription of -smooth muscle
actin (SMA) in endothelial cells favouring melanoma cells extrava-
sation [141]. Nevertheless, more work is needed to fully understand
the role of TGF in regulating endothelial homeostasis during can-
cer dissemination.
4.3. TGFˇ signalling in secondary organ colonisation
Cancer cells that reach a secondary site after extravasation need
to proliferate to form secondary tumours (Fig. 3). In lung cancer,
TGF has been shown to support metastasis in mouse models
[143]. In fact, activation of TGF-dependent transcription by R-
SMAD activators, such as proﬁlin2 and PREP1, results in enhanced
metastasis formation [29,104]. Moreover, TGF/Snail-driven EMT
suppresses fatty acid synthase (FASN) expression in lung cancer
cells, which is sufﬁcient to stimulate migration and extravasation
in vitro, as well as lung metastasis in vivo [144]. In breast can-nduced transcription in cancer, Semin Cancer Biol (2016),
cer, TGF induces HMGA2 expression via SMAD signalling during
EMT  [105], which induces metastasis [145]. Furthermore, loss-
of-function mutations in TGF repressors such as MED12 [146],
SIRT1 [147] and DEAR1 [148] results in invasion and metastasis.
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Fig. 3. The metastatic cascade. Diagram summarising the progression of cancer metastasis. Proliferating cells begin invading through the extracellular matrix as groups
or  individually, interacting with other cells in the tumour microenvironment. They eventually encounter blood vessels, which they enter through a process known as
intravasation. While in the vessel, cancer cells are transported by the blood ﬂow all over the body. They eventually form loose attachments to the endothelial cells (tethering),
w  the ve
t t and r
o
I
a
a
c
a
m
t
n
l
[
m
t
o
f
T
t
5
t
i
shich  turn into ﬁrmer adhesion and eventually lead to extravasation, or exit from
he  extracellular matrix as well as with other cells in the tumour microenvironmen
range.
n HCC, TGF induces long non-coding RNA LncRNA-ATB, which
ctivates the invasion-metastasis cascade [149]. LncRNA-ATB [150]
nd LncRNA-HIT [151] high expression levels have also been asso-
iated with EMT, invasion and metastasis in breast cancer. In
ddition, TGF-induced lysyl oxidase-like 2 (LOXL2) transcription
ay  also contribute to HCC intrahepatic and extrahepatic metas-
asis by modifying the tumour microenvironment and metastatic
iche [152]. In prostate cancer, TGF-driven transcription has been
inked to bone metastasis through the activation of mTOR pathway
153–155] and TGF-dependent ALCAM expression drives bone
etastasis [155]. In melanoma, TGF-SMAD2-CITED1 mediated
ranscription is necessary for melanoma metastasis [127]. More-
ver, TGF derived from platelets promotes melanoma metastasis
ormation [156] and expression of EWI2 – a negative regulator of
GF signalling – is associated with decreased metastasis forma-
ion [157].
. Concluding remarksPlease cite this article in press as: G. Cantelli, et al., TGFB-i
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TGF-induced transcription exerts a profound inﬂuence on
umour cells and stroma. Strong evidence indicates that while early
n cancer progression TGF plays a tumour suppressor role, in later
tages it is a potent pro-metastatic mediator. TGF can thereforessel. The extravasated cells colonise the new metastatic niche by interacting with
esuming proliferation to form a secondary tumour. TGF effects are highlighted in
be considered a general metastasis promoter and an interesting
therapeutic target.
Several inhibitors of the TGF pathway are being developed
and clinically tested for a number of cancers, including glioma,
pancreatic cancer, non-small-cell lung carcinoma, advanced HCC
and melanoma [158–161]. A phase II clinical trial with Galu-
nisertib, a TRI inhibitor, is currently on-going in patients with
advanced HCC (NCT01246986, http://clinicaltrials.gov). Moreover,
a vaccine targeting TGF2 (belagenpumatucel-L) has undergone
phase III clinical trials in lung cancer patients [162], where it has
yielded promising results. In metastatic melanoma patients, the
two most promising drugs targeting TGF signalling are Fresolu-
minab (GC1008, Genzyme) and Trabedersen (AP-12009, Antisense
Pharma), both targeting the TGF ligands. GC1008 has been tested
in phase I/II trials, where it has obtained mixed results prob-
ably reﬂecting the contrasting roles of TGF. GC1008 hindered
metastatic progression of melanoma, but also lead to the devel-
opment of non-melanoma cutaneous malignancies [163].
These past and current trials aimed to target either TGF ligands
or their receptors. Therefore, they are subject to dangerous side-nduced transcription in cancer, Semin Cancer Biol (2016),
effects and reduced effectiveness as a result of their impact on the
tumour suppressing actions of TGF. However, the body of work
presented in this review clearly indicates that the transcriptional
effects of TGF signalling are key to mediate its pro-metastatic
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ffects. Thus, we can hypothesize that drugs directed against the
ranscriptional targets and regulators of the TGF pathway might
e able to block the pro-metastatic effects of TGF signalling with-
ut compromising its tumour suppressor role.
Importantly, the tumour microenvironment should be taken
nto consideration when targeting the TGF pathway. Consider-
ng the discussed effects TGF exerts on both innate and adaptive
mmune cells, it is essential to understand how targeting the TGF
athway would affect tumour immunity. Immune cell screening,
uch as Treg frequency and phenotypic alterations, systemically
nd in the tumour site before and after TGF-targeted therapy
ould be incorporated as potential prognostic tools for cancer
atients.
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